Adjuvant tamoxifen may reduce recurrence risk for patients with ‘good-risk’ DCIS who forgo radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...
Adjuvant radiation and endocrine therapy significantly reduce locoregional recurrence in early-stage breast cancer post-lumpectomy, especially in low-risk patients. Radiation therapy notably decreases ...
Overall, the median time from biopsy to treatment was 35 days, but differed significantly between patients whose diagnosis and treatment occurred at the same center (31 days) versus those who sought a ...
Waiting and seeing is not often the strategy employed when it comes to treating breast cancer, but a new clinical trial by ...
With breast cancer now afflicting nearly 1 in 7 women in the United States, it was entirely appropriate for the first annual Oncology World Congress to dedicate a plenary session to discussing ...
LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...
Type C FDA Meeting Requested, Update Expected by Year-End 2025 SEATTLE, Sept. 8, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback